| Drug Name |
Darunavir |
| Drug ID |
BADD_D00586 |
| Description |
Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as [ritonavir] for the effective management of HIV-1 infection.[L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006.[L9227]
Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection.[A191682] Clinical trials are underway and are expected to conclude in August 2020.[L12066] |
| Indications and Usage |
Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
J05AE10 |
| DrugBank ID |
DB01264
|
| KEGG ID |
D03656
|
| MeSH ID |
D000069454
|
| PubChem ID |
213039
|
| TTD Drug ID |
D03IGH
|
| NDC Product Code |
70518-1483; 59676-566; 50370-0037; 68554-0035; 59676-562; 65015-880; 59676-564; 59676-563; 68554-0114; 65015-761; 42385-728; 47621-302; 53104-7694; 59676-565 |
| Synonyms |
Darunavir | Prezista | UIC-94017 | UIC 94017 | UIC94017 | Darunavir Ethanolate | Ethanolate, Darunavir | TMC 114 | 114, TMC | TMC114 | TMC-114 |
